A pilot study: Nano‐hydroxyapatite‐PEG/PLA containing low dose rhBMP2 stimulates proliferation and osteogenic differentiation of human bone marrow derived mesenchymal stem cells

Background Bone morphogenetic protein 2 (BMP2) can enhance posterolateral spinal fusion (PLSF). The minimum effective dose that may stimulate mesenchymal stem cells however remains unknown. Nano-hydroxyapatite (nHAp) polyethylene glycol (PEG)/polylactic acid (PLA) was combined with recombinant human BMP2 (rhBMP2). We in vitro evaluated proliferation, differentiation, and osteogenic genes of bone marrow 0.5, 1.0, 3.0 μg/mL rhBMP2 doses this study. Methods In experimental study designed to proliferation by a real-time quantitative cell analysis system the differentiation alkaline phosphatase (ALP) activity marker (Runx2, OPN, OCN) gene expressions derived (hBMMSCs). nHAp produced wet chemical process characterized Fourier transform infrared spectrophotometer, scanning electron microscopy, energy-dispersive x-ray spectroscopy. PEG/PLA polymer at 51:49 molar ratio. polymers. hBMMSCs were multipotency assays surface markers assessed flow cytometer. hBMMSC-rhBMP2 containing nHAp-PEG/PLA composite interaction transmission microscopy. Proliferative effect analysis, capacity ALP assay qPCR. Results hBMMSC 0.5 + 1.0 groups higher compared control. composites induced on days 3 10. application stimulated Runx2 OPN expressions. Conclusion differentiation. low formation future clinical PLSF applications.